Answers are grounded in this paper and cite their sources.
Epigenetic dysregulation drives many of the hallmarks of cancer by enabling aberrant gene expression programs which underlie cancer cellular plasticity and tumor heterogeneity phenotypes that promote cancer initiation, progression, metastasis and drug resistance 1 . Indeed, one of the key findings of the genomics era in cancer biology has been that most cancer genomes are epigenetically abnormal and mutations in genes that regulate DNA methylation, such as DNMT3A/B , TET1-3 and IDH1/2 , are prevalent 2 , 3 . Together, these observations suggest that epigenetic dysregulation promotes cancer but may also represent a targetable vulnerability. As such, there has been substantial interest in the development of anti-cancer strategies which modulate cancer associated epigenetic programs and dependencies 4 , 5 , 6 . One such promising strategy which has shown success in the context of certain subtypes of acute myeloid leukemia (AML) is to inhibit the activity of key enzymes required for maintenance and regulation of DNA methylation by small molecule drugs, such as decitabine, resulting in global DNA hypomethylation. There is clear evidence of clinical benefit of decitabine treatment for AML patients who have cytogenetic abnormalities associated with unfavorable risk, TP53 mutations or both (defined hereafter as high-risk AML patients) 7 , 8 . Unfortunately, despite this benefit, most AML patients eventually progress following decitabine treatment with a median overall survival of less than 1 year. Problematically, relatively little progress has been made on improving the clinical activity of DNA hypomethylating agents (HMA) such as decitabine in AML or other cancers in part because the molecular determinants of response to HMAs are unclear.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: